Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 7 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive DiseaseTerminatedNCT04685499Phase 2Results posted Report a problem
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyCompletedNCT04676412Phase 3Results posted Report a problem
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast CancerCompletedNCT04674306Early Phase 1Results posted Report a problem
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2Results posted Report a problem
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04633278Phase 2Results posted Report a problem
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04601857Phase 2Results posted Report a problem
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerTerminatedNCT04590781Phase 1/2Results posted Report a problem
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerActive, not recruitingNCT04576091Phase 1Results posted Report a problem
BO-112 With Pembrolizumab in Unresectable Malignant MelanomaCompletedNCT04570332Phase 2Results posted Report a problem
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted Report a problem
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCTerminatedNCT04524689Phase 2Results posted Report a problem
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)TerminatedNCT04521621Phase 1/2Results posted Report a problem
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver MetastasisTerminatedNCT04508140Phase 2Results posted Report a problem
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent GlioblastomaCompletedNCT04479241Phase 2Results posted Report a problem
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04478695Phase 1Results posted Report a problem
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT04475939Phase 3Results posted Report a problem
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersActive, not recruitingNCT04430738Phase 2Results posted Report a problem
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04428333Phase 3Results posted Report a problem
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsCompletedNCT04420884Phase 1/2Results posted Report a problem
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesTerminatedNCT04418661Phase 1/2Results posted Report a problem
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)TerminatedNCT04394624Phase 2Results posted Report a problem
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesCompletedNCT04383938Phase 1/2Results posted Report a problem
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid TumorsCompletedNCT04381650Phase 1/2Results posted Report a problem
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerActive, not recruitingNCT04373031Phase 2Results posted Report a problem
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell CarcinomaCompletedNCT04369937Phase 2Results posted Report a problem
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted Report a problem
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedNCT04306900Phase 1Results posted Report a problem
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedNCT04305041Phase 1/2Results posted Report a problem
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedNCT04303169Phase 1/2Results posted Report a problem
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsCompletedNCT04260529Phase 1/2Results posted Report a problem
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentCompletedNCT04256707Phase 1/2Results posted Report a problem
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCActive, not recruitingNCT04251117Phase 1/2Results posted Report a problem
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted Report a problem
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingNCT04225117Phase 2Results posted Report a problem
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)CompletedNCT04220866Phase 2Results posted Report a problem
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung CancerActive, not recruitingNCT04216316Phase 1/2Results posted Report a problem
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedNCT04199104Phase 3Results posted Report a problem
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2Results posted Report a problem
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedNCT04191135Phase 2Results posted Report a problem
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast CancerTerminatedNCT04190056Phase 2Results posted Report a problem
Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersTerminatedNCT04171219Phase 2Results posted Report a problem
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)CompletedNCT04165096Phase 2Results posted Report a problem
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)CompletedNCT04165083Phase 2Results posted Report a problem
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsTerminatedNCT04157517Phase 1/2Results posted Report a problem
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedNCT04152863Phase 2Results posted Report a problem
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and NeckActive, not recruitingNCT04150900Phase 2Results posted Report a problem
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted Report a problem
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2Results posted Report a problem
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted Report a problem
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)TerminatedNCT04135352Phase 1Results posted Report a problem
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04128696Phase 3Results posted Report a problem
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer PatientsCompletedNCT04099641Phase 2Results posted Report a problem
A Study of LY3435151 in Participants With Solid TumorsTerminatedNCT04099277Phase 1Results posted Report a problem
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast CancerTerminatedNCT04095689Phase 2Results posted Report a problem
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerActive, not recruitingNCT04090528Phase 2Results posted Report a problem
FPT155 in Patients With Advanced Solid TumorsTerminatedNCT04074759Phase 1Results posted Report a problem
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHNTerminatedNCT04034225Phase 1/2Results posted Report a problem
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCTerminatedNCT04032847Phase 1/2Results posted Report a problem
A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted Report a problem
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04027946Phase 2Results posted Report a problem
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceCompletedNCT04013672Phase 2Results posted Report a problem
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedNCT03996473Phase 1Results posted Report a problem
CMP-001 for Relapsed and Refractory LymphomaTerminatedNCT03983668Phase 1/2Results posted Report a problem
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)CompletedNCT03976362Phase 3Results posted Report a problem
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)CompletedNCT03976323Phase 3Results posted Report a problem
Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaTerminatedNCT03957551Phase 1/2Results posted Report a problem
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)TerminatedNCT03948763Phase 1Results posted Report a problem
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck CancerTerminatedNCT03937141Phase 2Results posted Report a problem
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaCompletedNCT03921021Phase 2Results posted Report a problem
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction CancerCompletedNCT03918499Phase 1/2Results posted Report a problem
GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03917381Phase 1/2Results posted Report a problem
A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma PhenotypeCompletedNCT03910660Phase 1/2Results posted Report a problem
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)CompletedNCT03898180Phase 3Results posted Report a problem
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid TumoursTerminatedNCT03894540Phase 1Results posted Report a problem
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersCompletedNCT03884556Phase 1Results posted Report a problem
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesTerminatedNCT03881488Phase 1Results posted Report a problem
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results posted Report a problem
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03867175Phase 3Results posted Report a problem
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03848845Phase 1/2Results posted Report a problem
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung CancerCompletedNCT03847519Phase 1/2Results posted Report a problem
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic MetastasesTerminatedNCT03844750Phase 2Results posted Report a problem
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active, not recruitingNCT03835819Phase 2Results posted Report a problem
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)TerminatedNCT03833427Phase 1Results posted Report a problem
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Phase 3Results posted Report a problem
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)CompletedNCT03829319Phase 3Results posted Report a problem
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatTerminatedNCT03823131Phase 2Results posted Report a problem
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results posted Report a problem
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.CompletedNCT03815058Phase 2Results posted Report a problem
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted Report a problem
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPCTerminatedNCT03792841Phase 1Results posted Report a problem
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaTerminatedNCT03776864Phase 2Results posted Report a problem
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)TerminatedNCT03769467Phase 1/2Results posted Report a problem
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaCompletedNCT03765229Phase 2Results posted Report a problem
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedNCT03761914Phase 1/2Results posted Report a problem
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell CancerTerminatedNCT03747484Phase 1/2Results posted Report a problem
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)TerminatedNCT03739138Phase 1Results posted Report a problem
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerActive, not recruitingNCT03734692Phase 1/2Results posted Report a problem
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedNCT03727880Phase 2Results posted Report a problem
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerTerminatedNCT03723915Phase 2Results posted Report a problem
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabTerminatedNCT03709706Phase 1/2Results posted Report a problem

← Pembrolizumab